Marker Therapeutics’ Phase 1 APOLLO study of MT-601 in relapsed B-cell lymphoma patients yielded a 66% objective response rate (ORR) in the Non-Hodgkin Lymphoma (NHL) cohort, with 50% of patients achieving a complete response (CR). No dose-limiting toxicities (DLTs) or immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. The trial will now proceed to dose expansion, focusing on patients with Diffuse Large B-Cell Lymphoma (DLBCL) who are post-CAR-T relapse or ineligible for CAR-T.
This data represents a significant step for Marker, potentially carving out a niche for MT-601 in the increasingly complex landscape of lymphoma treatment. While CAR-T therapies have revolutionized treatment, a considerable portion of patients relapse, highlighting the urgent need for effective salvage options. MT-601, a multi-antigen recognizing (MAR) T-cell therapy targeting six lymphoma-associated antigens, offers a non-genetically modified approach, potentially streamlining manufacturing and mitigating safety concerns often associated with engineered T-cell therapies.
The study’s emphasis on patients with prior CAR-T exposure, particularly those with DLBCL, reflects a strategic focus on addressing a high unmet need within a well-defined population. This targeting could facilitate faster regulatory pathways and more precise commercial positioning. The absence of DLTs and ICANS, even at higher doses, differentiates MT-601 from other cellular therapies and may offer a wider therapeutic window, particularly relevant for this heavily pre-treated patient population.
The observed efficacy, even at lower doses, in conjunction with the safety profile, could impact site operations by simplifying patient management and potentially reducing the need for intensive monitoring. The non-genetically modified nature of MAR-T cells could also influence vendor relationships and supply chain dynamics, potentially leading to more decentralized manufacturing processes. This aligns with broader industry trends towards decentralized trials and personalized medicine approaches.
While the initial results are promising, the durability of response and long-term efficacy in a larger patient cohort will be crucial. The upcoming dose expansion phase will be crucial for confirming these initial findings and evaluating the effects of the maximum dose. Marker’s manufacturing capacity and its ability to scale production efficiently will also be a factor as it moves towards potential commercialization. The trial’s progress will be closely watched, as it could offer insights into the viability of MAR-T technology as a post-CAR-T option and influence the future development of non-genetically modified cellular immunotherapies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
